Capmatinib (capatinib) China launch status and detailed explanation of indications in 2024

Recently, good news has come from the treatment field of non-small cell lung cancer (NSCLC) in China. An innovative drug, capmatinib (trade name: Touradida, chemical composition: capmatinib hydrochloride tablets), has successfully entered the Chinese market. As the world's first MET inhibitor approved by the U.S. Food and Drug Administration (FDA), capmatinib has opened up a new treatment path for NSCLC patients carrying mesenchymal epithelial transition factor (MET) exon 14 skipping mutations.

Capmatinib is known for its highly selectiveMET kinase inhibitory effect. Its unique mechanism lies in its ability to precisely inhibit the abnormal activation of the MET pathway, thereby effectively curbing the proliferation and survival of tumor cells. The MET gene is closely linked to the occurrence and development of tumors. When a specific fusion mutation or exon 14 skipping occurs in this gene, it will lead to the overexpression of the MET gene and accelerate the growth, invasion and metastasis of tumor cells. Capmatinib blocks the growth and spread of tumors by inhibiting this abnormally activated MET protein, bringing new treatment hope to patients.

Capmatinib is particularly suitable for adult patients with locally advanced or metastatic NSCLC who have not received systemic treatment and carryMET exon 14 skipping mutations. Although the proportion of such mutations in NSCLC patients is not high, conventional treatments have limited effect on them. Therefore, the launch of capmatinib provides a new treatment option and hope for these patients.

In terms of medication guidance, the recommended dose of capmatinib is 400 mg orally twice daily. Patients can take it before or after meals according to their own conditions. It is important that patients swallow the tablets whole and avoid breaking, crushing or chewing them. If you occasionally miss a dose or vomit a dose, there is no need to take it again, just continue taking the next dose as scheduled.

Although capmatinib has been launched in China, some pharmacies may not be able to provide the drug temporarily as the market supply is still in its early stages. However, with the gradual stabilization and expansion of production and supply, it is believed that this innovative drug will soon benefit more patients in need of treatment and bring them new hope.